Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (1): 47-55.DOI: 10.3969/j.issn.1673-8640.2020.01.011
Previous Articles Next Articles
ZHAO Zheng, LI Yi, YANG Feixiang
Received:
2019-07-11
Online:
2020-01-30
Published:
2020-02-28
CLC Number:
ZHAO Zheng, LI Yi, YANG Feixiang. Role of NKX2-5 on tamoxifen resistance in breast cancer patients and its regulation mechanism[J]. Laboratory Medicine, 2020, 35(1): 47-55.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.01.011
患者来源 | 例数 | 年龄/岁 | TNM分期 | ER表达 | PR表达 | HER-2表达 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ⅰ期 | Ⅱ期 | Ⅲ期 | Ⅳ期 | 阳性 | 阴性 | 不详 | 阳性 | 阴性 | 不详 | 阳性 | 阴性 | 不详 | ||||||
本研究 | 50 | 44.5±9.4 | 8 | 23 | 17 | 2 | 37 | 13 | 0 | 32 | 18 | 0 | 21 | 29 | 0 | |||
GEO | 104 | 45.1±8.7 | 18 | 52 | 27 | 7 | 67 | 30 | 7 | 60 | 24 | 20 | 30 | 62 | 12 |
患者来源 | 例数 | 年龄/岁 | TNM分期 | ER表达 | PR表达 | HER-2表达 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ⅰ期 | Ⅱ期 | Ⅲ期 | Ⅳ期 | 阳性 | 阴性 | 不详 | 阳性 | 阴性 | 不详 | 阳性 | 阴性 | 不详 | ||||||
本研究 | 50 | 44.5±9.4 | 8 | 23 | 17 | 2 | 37 | 13 | 0 | 32 | 18 | 0 | 21 | 29 | 0 | |||
GEO | 104 | 45.1±8.7 | 18 | 52 | 27 | 7 | 67 | 30 | 7 | 60 | 24 | 20 | 30 | 62 | 12 |
细胞株 | TAM/(μmol/L) | |||
---|---|---|---|---|
5 | 20 | 50 | 100 | |
MCF-7 | 26.3±3.7 | 89.4±5.8 | 91.4±6.7 | 82.4±6.5 |
T47D | 28.2±2.5 | 47.8±7.1 | 63.5±10.4 | 63.4±5.3 |
BCAP37 | 21.7±4.3 | 31.2±4.7 | 68.1±6.4 | 60.7±5.2 |
SKBR3 | 25.2±3.1 | 38.5±7.3 | 58.6±5.4 | 54.6±6.6 |
MCF-7/TAM | 24.5±3.7 | 31.6±5.3 | 53.1±6.1 | 50.4±4.8 |
细胞株 | TAM/(μmol/L) | |||
---|---|---|---|---|
5 | 20 | 50 | 100 | |
MCF-7 | 26.3±3.7 | 89.4±5.8 | 91.4±6.7 | 82.4±6.5 |
T47D | 28.2±2.5 | 47.8±7.1 | 63.5±10.4 | 63.4±5.3 |
BCAP37 | 21.7±4.3 | 31.2±4.7 | 68.1±6.4 | 60.7±5.2 |
SKBR3 | 25.2±3.1 | 38.5±7.3 | 58.6±5.4 | 54.6±6.6 |
MCF-7/TAM | 24.5±3.7 | 31.6±5.3 | 53.1±6.1 | 50.4±4.8 |
组别 | TAM/(μmol/L) | |||
---|---|---|---|---|
5 | 20 | 50 | 100 | |
Ad-NKX2-5组 | 8.7±0.5 | 21.4±5.7 | 56.9±10.1* | 67.9±7.8* |
Ad-NC组 | 4.3±0.4 | 19.7±4.5 | 28.9±7.3 | 49.7±7.1 |
NKX2-5- siRNA组 | 19.8±5.4 | 38.9±6.2*# | 40.9±5.4*# | 40.5±5.6*# |
NC-siRNA组 | 21.2±6.5 | 59.4±8.4 | 60.1±8.9 | 67.7±7.6 |
组别 | TAM/(μmol/L) | |||
---|---|---|---|---|
5 | 20 | 50 | 100 | |
Ad-NKX2-5组 | 8.7±0.5 | 21.4±5.7 | 56.9±10.1* | 67.9±7.8* |
Ad-NC组 | 4.3±0.4 | 19.7±4.5 | 28.9±7.3 | 49.7±7.1 |
NKX2-5- siRNA组 | 19.8±5.4 | 38.9±6.2*# | 40.9±5.4*# | 40.5±5.6*# |
NC-siRNA组 | 21.2±6.5 | 59.4±8.4 | 60.1±8.9 | 67.7±7.6 |
[1] | ZENG H,CHEN W,ZHENG R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health,2018,6(5):e555-e567. |
[2] | BLOK E J,DERKS M G,VAN DER HOEVEN J J,et al. Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer:current and future evidence[J]. Cancer Treat Rev,2015,41(3):271-276. |
[3] | PRASHANTH KUMAR B N,RAJPUT S,BHARTI R,et al. BI2536-A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells[J]. Biomed Pharmacother,2015,74:124-132. |
[4] | GEORGE V,COLOMBO S,TARGOFF K L.An early requirement for nkx2.5 ensures the first and second heart field ventricular identity and cardiac function into adulthood[J]. Dev Biol,2015,400(1):10-22. |
[5] | KWABI-ADDO B,WANG S,CHUNG W,et al.Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men[J]. Clin Cancer Res,2010,16(14):3539-3547. |
[6] | GRAZIANI G,ARTUSO S,DE LUCA A,et al.A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib[J]. Biochem Pharmacol,2015,95(1):16-27. |
[7] | LI G,ZHANG J,JIN K,et al.Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells[J]. Mol Oncol,2013,7(3):611-624. |
[8] | KOOL M,FONTEIN D B,MEERSHOEK-KLEIN KRANENBARG E,et al. Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients[J]. Breast,2015,24(3):224-229. |
[9] | YE W,WANG J,SONG Y,et al.A common Shox2-Nkx2-5 antagonistic mechanism primes the pacemaker cell fate in the pulmonary vein myocardium and sinoatrial node[J]. Development,2015,142(14):2521-2532. |
[10] | JEONG H S,JUNG E S,SIM Y J,et al.Fbxo25 controls Tbx5 and Nkx2-5 transcriptional activity to regulate cardiomyocyte development[J]. Biochim Biophys Acta,2015,1849(6):709-721. |
[11] | KOJIC S,NESTOROVIC A,RAKICEVIC L,et al.Cardiac transcription factor Nkx2.5 interacts with p53 and modulates its activity[J]. Arch Biochem Biophys,2015,569:45-53. |
[12] | DAREMIPOURAN M,WANG S P,ELLIS A,et al.NKX2-5,a potential tumor suppressor gene in prostate cancer[J]. Cancer Res,2011,71(8):3033. |
[13] | 杨莉,阮文静,陈恩国,等. 血清NKX2-1蛋白在原发性肺癌患者中的诊断价值[J]. 浙江大学学报(医学版),2012,41(5):535-539. |
[14] | 杨莉. NKX2-1在肺癌细胞中的生物学效应及与抗癌药物耐药性关系的研究[D]. 杭州:浙江大学,2011. |
[15] | ALCÁNTARA-ORTIGOZA M A,DE RUBENS-FIGUEROA J,REYAN-FABIAN M E,et al. Germline mutations in NKX2-5,GATA4,and CRELD1 are rare in a Mexican sample of Down syndrome patients with endocardial cushion and septal heart defects[J]. Pediatr Cardiol,2015,36(4):802-808. |
[16] | LI C M,GOCHEVA V,OUDIN M J,et al.Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis[J]. Genes Dev,2015,29(17):1850-1862. |
[17] | CHANG N J,WENG W H,CHANG K H,et al.Genome-wide gene expression profiling of ischemia-reperfusion injury in rat kidney,intestine and skeletal muscle implicate a common involvement of MAPK signaling pathway[J]. Mol Med Rep,2015,11(5):3786-3793. |
[18] | DANG N,PANG S,SONG H,et al.Knockdown of filaggrin influences the epidermal terminal differentiation via MAPK pathway in normal human epidermal keratinocytes[J]. Mol Biol Rep,2015,42(2):337-343. |
[19] | XU C,SUN X,QIN S,et al.Let-7a regulates mammosphere formation capacity through Ras/NF-κ B and Ras/MAPK/ERK pathway in breast cancer stem cells[J]. Cell Cycle,2015,14(11):1686-1697. |
[20] | QI X,YIN N,MA S,et al.p38γ MAPK is a therapeutic target for triple-negative breast cancer by stimulation of cancer stem-like cell expansion[J]. Stem Cells,2015,33(9):2738-2747. |
[21] | 张闻龙,卢仁泉,江铭磊,等. 血浆热休克蛋白90α在乳腺癌诊疗中的应用价值[J]. 检验医学,2017,32(5):374-377. |
[1] | WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817. |
[2] | CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578. |
[3] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429. |
[4] | LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239. |
[5] | LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147. |
[6] | GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206,miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068. |
[7] | WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820. |
[8] | YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517. |
[9] | SUN Xiaodan, XU Jing, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Inhibitory effects of antiestrogen on the proliferation and CCL2 expression of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(4): 319-324. |
[10] | YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348. |
[11] | ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40. |
[12] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
[13] | YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329. |
[14] | LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158. |
[15] | JIN Shu, ZHU Qi, ZHU Yuan, YUAN Ya, CAI Xiaoyao, ZHANG Ji, YAN Peiyi. Methylation level and mRNA expression of CpG island of HER2 gene in breast cancer and its adjacent tissues [J]. Laboratory Medicine, 2020, 35(5): 481-486. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||